Masanori Miura

Learn More
We measured liver fat content by 3-Tesla magnetic resonance spectroscopy (MRS) in 34 non- to mild obese Japanese subjects with type 2 diabetes, who were not complicated with any liver diseases including clinical fatty liver (liver/spleen ratio of computed tomography [CT] < 0.9) and were not being treated with oral hypoglycemic agents, insulin, or(More)
CONTEXT Blackcurrant (Ribes nigrum L.) is a classical fruit that has long been used to make juice, liqueur and sometimes medicines in Europe. The beneficial effects of blackcurrant, which are inhibition of lipopolysaccharide-stimulated inflammatory, anticarcinogenesis and other health effects, have been reported. OBJECTIVE Previously, we reported the(More)
We compared clinical features and vascular complications of patients with diabetes mellitus associated with liver cirrhosis versus patients with type 2 diabetes mellitus. Subjects were 19 patients (LC-DM group) in whom diabetes was diagnosed after development of liver cirrhosis. Control consisted of 38 patients with type 2 diabetes (T2DM group) matched for(More)
Coagulation factor V (FV) deficiency is a rare bleeding disorder characterized by low coagulant and antigen levels of FV with bleeding symptoms ranging from mild to severe. Only a limited number of mutations have been reported because of the large size of the factor V gene (F5) as well as the low prevalence. In this study, we have identified four novel(More)
We found the novel selective and orally available non-amidine TF/FVIIa complex inhibitor 21e, 4-({[(1S)-(aminocarbonyl)-3-methylbutyl]amino}carbonyl)-2'-({[4- (aminomethyl)phenyl]amino}carbonyl)-4'-(methylamino)biphenyl-2- carboxylic acid. The derivatives were synthesized by conversions of the isobutyl moiety and the introduction of alkylamino groups to(More)
Inhibition of tissue factor/factor VIIa complex (TF/FVIIa) is an attractive strategy for antithrombotic therapies. We began with an investigation of a non-amidine TF/FVIIa inhibitor based on a modification of amidine compound 1. Optimization of the substituents on the P1 phenyl portion of the compound 1 led to a neutral or less basic alternative for the(More)
[5] 111 Mototsugu Ishii, Yoshichika Yoshioka, Wataru Ishida, Yoshihito Kaneko, Fumikado Fujiwara, Haruhito Taneichi, Masanori Miura, Makiko Toshihiro, Noriko Takebe, Masakatsu Iwai, Kazuyuki Suzuki and Jo Satoh. "Liver Fat Content Measured by Magnetic Resonance Spectroscopy at 3.0 Tesla Independently Correlates with Plasminogen Activator Inhibitor-1 and(More)
Received December 14, 2004; revision accepted for publication January 14, 2005. Correspondence: Jo Satoh, Department of Diabetes and Metabolism, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan. e-mail: fufuji@iwate-med. ac.jp, jsatoh@iwate-med.ac.jp Low Incidence of Vascular Complications in Patients with Diabetes Mellitus Associated with(More)
  • 1